Andere talen Tempest Therapeutics, Inc.

Aandelen

TPST

US87978U1088

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,54 ^USD	+1,72%		+14,19%	-19,55%

09/04	Tempest Therapeutics, Inc. Rapporteert nieuwe preklinische gegevens voor TPST-1120 in RCC op de jaarlijkse bijeenkomst van de AACR	CI
04/04	Tempest Therapeutics, Inc. Kondigt de publicatie aan van positieve gegevens van de Fase 1-studie met TPST-1120 bij patiënten met gevorderde vaste tumoren in het Journal of Cancer Research Communications	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	26/04
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	10/04
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	09/04
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	09/04
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics : Corporate Presentation - April 2024	29/03
Tempest Therapeutics : Corporate Presentation - March 2024	22/03
Tempest Reports Year End 2023 Financial Results and Provides Business Update	20/03
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tempest Reports Year End 2023 Financial Results and Provides Business Update	19/03
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K	19/03
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)	14/03
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting	05/03
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26/02
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Tempest Therapeutics, Inc.

Aandelen

TPST

US87978U1088

Andere talen

Filters